100mg SPN-812 + Placebo

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Attention-Deficit/Hyperactivity Disorder

Conditions

Attention-Deficit/Hyperactivity Disorder

Trial Timeline

Mar 19, 2024 → Jun 1, 2026

NCT ID

NCT04781140

About 100mg SPN-812 + Placebo

100mg SPN-812 + Placebo is a approved stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04781140. Target conditions include Attention-Deficit/Hyperactivity Disorder.

What happened to similar drugs?

7 of 10 similar drugs in Attention-Deficit/Hyperactivity Disorder were approved

Approved (7) Terminated (0) Active (3)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04781140	Approved	Recruiting	Mar 19, 2024	Jun 1, 2026	Attention-Deficit/Hyperactivity Disorder

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812	Supernus Pharmaceuticals	Phase 2	29
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29